Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer

J Clin Oncol. 2016 May 20;34(15):1715-7. doi: 10.1200/JCO.2015.66.2320. Epub 2016 Mar 14.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Androgen Antagonists*
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms*
  • Radiotherapy Dosage

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen